Sanofi S.A., FR0000120578

Sanofi stock falls 3.13 percent after Regeneron deal expands pipeline costs

Published on 10/03/2026 at 22:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock traded at EUR 70.810 on October 2, 2026, near its EUR 69.750 yearly low. Q2 net sales reached EUR 11.6 billion, up 17.8 percent, while consensus target was EUR 92.50.

Modern pharmaceutical sterile fill-and-finish manufacturing facility interior with glass vial-filling machines and cleanroom workers in white suits — Sanofi FR0000120578 photorealistic sterile fill-and-finish facility with vial-filling machines and cleanroom workers, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) fell 3.13 percent to EUR 70.810 on Euronext Paris on October 2, 2026, only EUR 1.060 above its session low of EUR 69.750. The move followed Sanofi's agreement with Regeneron, which commits Sanofi to a $1 billion upfront payment for four long-acting antibodies.

Regeneron deal raises near term costs

According to Sanofi on October 1, 2026, Regeneron will receive the $1 billion upfront payment, with potential development, regulatory and commercial milestone payments of up to an additional $7 billion. The companies will share development and commercialization costs and split future profits from the programs equally.

The agreement adds four next-generation antibodies to the alliance, including REGN20423, which is already in a Phase 1 clinical study. The other three programs are expected to enter clinical studies in 2027, leaving investors to weigh immediate spending against a longer development timetable.

Q2 growth gives Sanofi a counterweight

Sanofi's Q2 2026 results supplied a stronger operating backdrop. The Yahoo Finance transcript states that net sales rose 17.8 percent to EUR 11.6 billion, while business EPS increased 33.3 percent in Q2 2026. The comparison is important because sales growth exceeded the rise in operating expenses, which was 13.1 percent.

Dupixent remained the main engine. Sales exceeded EUR 5 billion in Q2 2026 and increased 37 percent year over year, while vaccine sales declined 5 percent to EUR 1.15 billion, creating a clear split between the immunology franchise and the vaccine business.

Consensus target stays above EUR 92

Boursorama listed a three-month analyst consensus target of EUR 92.50 as of October 3, 2026, compared with the EUR 70.810 Euronext Paris price. That target stood 30.63 percent above the reference price, while the stock's 52-week range was EUR 69.750 to EUR 91.150.

The next company checkpoint is scheduled for October 30, 2026. Sanofi's investor calendar identifies that date for the review of third-quarter 2026 results, making vaccine trends and pipeline spending the next quantified test for the shares.

Sanofi stock stays near yearly low

Sanofi stock was last quoted at EUR 70.810 on Euronext Paris on October 2, 2026. Its market capitalization was EUR 85.5 billion, and trading volume reached 3,817,639 shares, while the distance to the 52-week high remained EUR 20.340.